title: Risk factors for chronic kidney disease after chemotherapy for testicular cancer.
abstract: OBJECTIVE
  To elucidate the patterns of and risk factors for deterioration of renal function after chemotherapy in metastatic testicular cancer survivors using the estimated glomerular filtration rate.
  
  
  METHODS
  A total of 96 patients who were treated with cisplatin-based chemotherapy for metastatic testicular cancer between January 1981 and December 2010 were enrolled in this study. The estimated glomerular filtration rate was based on the serum creatinine concentration using the formula of the Japanese Society of Nephrology. Risk factors for chronic kidney disease were examined by multivariate logistic-regression analysis.
  
  
  RESULTS
  The median follow-up period was 70 months (range 15-342). The median pretreatment estimated glomerular filtration rate was 98 mL/min/1.73 m(2) (range 44-216), and it gradually decreased for 1 year after the end of chemotherapy, although there was no significant change in estimated glomerular filtration rate beyond 1 year. One year after chemotherapy, 22 of 96 patients (23%) showed chronic kidney disease (less than 60 mL/min/1.73 m(2) estimated glomerular filtration rate). The multivariate analysis showed that the patients with mild renal damage (estimated glomerular filtration rate 60-89 mL/min/1.73 m(2) ) and elevated blood pressure (higher than 130/80 mmHg) before treatment had a significant risk with odds ratios of 2.63 (95% confidence interval 1.09-6.73) and 4.22 (95% confidence interval 1.45-12.6), respectively.
  
  
  CONCLUSIONS
  Close monitoring of renal function is important for at least 1 year after chemotherapy for testicular cancer, especially in patients having elevated blood pressure and/or mild renal damage before chemotherapy.
authors.affiliation: Department of Urology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan.
authors.forename: Hiromu
authors.initials: H
authors.lastname: Inai
authors.forename: Koji
authors.initials: K
authors.lastname: Kawai
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ikeda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ando
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Kimura
authors.forename: Takehiro
authors.initials: T
authors.lastname: Oikawa
authors.forename: Mizuki
authors.initials: M
authors.lastname: Onozawa
authors.forename: Jun
authors.initials: J
authors.lastname: Miyazaki
authors.forename: Katsunori
authors.initials: K
authors.lastname: Uchida
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nishiyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors; D018239:Seminoma / Q000188:drug therapy / Q000453:epidemiology / Q000556:secondary; D017741:Survivors / Q000706:statistics & numerical data; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000556:secondary; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin